Lily Wound, a partner in Goodwin’s Technology and Life Sciences groups, has extensive experience representing pharmaceutical, biotechnology, and other life sciences companies in a wide range of complex commercial, corporate, and licensing transactions, including those involving gene therapy, gene editing, engineered cell therapy, and genomic testing. With broad knowledge of licensing and collaboration matters, Ms. Wound has worked on some of the most complex life sciences collaborations in the industry and has handled transactions at every stage of the life cycle of a life sciences product, and has represented early stage to big pharma companies in connection with these transactions. In addition, her roster of domestic and international clients extends to the healthcare, healthcare information and technology, cosmetics, publishing, media, internet, software, and technology industries.

Ms. Wound is also a member of Goodwin’s PropSci practice which is focused on supporting the intersection of Real Estate and Life Sciences through thoughtful collaboration across the two practice areas. As a key contributor to the group and Steering Committee, Ms. Wound stays up to date on relevant market trends impacting the PropSci sector to effectively support clients involved in this space.

Ms. Wound joined Goodwin in 2019 from WilmerHale, where she served as counsel. She has also served as in-house counsel at Hearst Corporation, where she advised on all aspects of Hearst's businesses relating to healthcare information and technology, traditional media, new media, and digital media. Her responsibilities at Hearst included serving as general counsel for an evidence-based medical information and technology company and leading all complex transactions in the newspapers division.

Areas of Practice
Domaines D’Expertise





Ms. Wound’s representative matters include advising:

  • Serotiny, Inc. in its research collaboration with Janssen to use its AI-driven tMDP mining and design platform to optimize CAR designs for cellular therapy.
  •  SIGA Technologies in its international promotion agreement for TPOXX™ with Meridian Medical Technologies and its international procurement orders for TPOXX™ for health security preparedness in response to the monkeypox outbreak.
  • LEXEO Therapeutics in its acquisition of Stelios Therapeutics and its gene therapy programs for rare cardiovascular diseases.
  • EQRx in its strategic collaboration and license agreement with Hansoh Pharmaceutical for ex-China rights to its EGFR inhibitor, almonertinib, which is approved in China for EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).
  • EQRx in its license agreement with G1 Therapeutics for lerociclib, an oral CDK4/6 inhibitor, in the U.S., Europe, Japan and all other global markets, excluding the Asia-Pacific region (except Japan).
  • Landmark Bio in its formation as an industry-academia research and development consortium focused on innovations in gene and cell therapies and immunotherapies, advanced biologic innovation and manufacturing, and accelerating the practical application and commercialization of these therapies. Founding members include Harvard University, Fujifilm, Massachusetts Institute of Technology, Diosynth Biotechnologies, Cytiva (formerly part of GE Healthcare Life Sciences) and Alexandria Real Estate Equities, Inc. Landmark Bio recently closed on its initial $76 million fundraising round.
  • Editas Medicine in a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to discover, develop, and manufacture novel engineered cell medicines.*
  • Foundation Medicine in its partnership with Natera to develop and commercialize personalized circulating tumor DNA (ctDNA) monitoring assays.*
  • Voyager Therapeutics in a global strategic collaboration with AbbVie to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.*
  • Spark Therapeutics in its licensing and supply agreements with Novartis to develop and commercialize investigational voretigene neparvovec outside the United States.*
  • Spark Therapeutics in a licensing agreement with Selecta Biosciences for exclusive worldwide rights to Selecta's proprietary Synthetic Vaccine Particles platform technology.*
*Denotes experience prior to joining Goodwin.
Professional Activities

Ms. Wound serves on the Board of Managers of Life Sciences Cares New York, whose mission is to leverage the intellectual, financial, and human capital of the life sciences industry in an effort to reduce the effects of poverty.

Ms. Wound serves as an elected Board member of Asian Women for Health, a peer-led, community-based network dedicated to advancing Asian women’s health and wellness through education, advocacy, and support.

Ms. Wound has served for eight years as National Chair and Metro-NY Chair of Young Women In Bio, a national organization focused on promoting STEM, and supporting opportunities in STEM, to girls from elementary school through high school. Young Women in Bio is part of Women in Bio.


In The News









The George Washington University Law School
Boston University School of Public Health
B.A., Biochemical Sciences
Harvard University



New York
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique